Bionomics Limited (ASX: BNO) is preparing a capital raising announcement, with the ASX granting the company a trading halt today, while placing its shares in pre-open.
The biotechnology company is focused on innovative therapeutics for cancer and diseases of the central nervous system.
Bionomics has small molecule product development programs in the areas of cancer, anxiety, memory loss and autoimmune disorders, several of which are in or approaching clinical development stage.
The halt will last until the earlier of an announcement being made to the market, or the opening of trade on Monday 4th March 2013.
Proactive Investors Australia is the market leader in producing news, articles and research reports on ASX “Small and Mid-cap” stocks with distribution in Australia, UK, North America and Hong Kong / China.